Citizens analyst Reni Benjamin reiterated a Market Outperform rating and $40.00 price target on Summit Therapeutics plc (NASDAQ: SMMT).The analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE